GuidoDalbagniMD

Professor, Urology, Weill Cornell Medical College

Overview of Dr. Dalbagni

Dr. Guido Dalbagni is an urologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Sloan Kettering Bergen. He received his medical degree from Cairo University School of Medicine and has been in practice 37 years. Dr. Dalbagni accepts several types of health insurance, listed below. He is one of 72 doctors at Memorial Sloan Kettering Cancer Center and one of 2 doctors at Memorial Sloan Kettering Bergen who specialize in Urology. He has more than 100 publications and over 500 citings.

Office
1275 York Ave
New York, NY 10065
Book by Phone+1(631) 458-1773

Education & Training

NYU Grossman School of MedicineResidency, Urology, 1984 - 1988
Icahn School of Medicine at Mount Sinai (Cabrini)Residency, Surgery, 1982 - 1984
Cairo University School of MedicineClass of 1980

Certifications & Licensure

NY State Medical License 1989 - 2026
NJ State Medical License 1986 - 2025
American Board of Urology Urology

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons

Clinical Trials

Quality of Life in Patients With Bladder Cancer Start of enrollment: 2008 Aug 01
Active, not recruiting
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer Start of enrollment: 2009 Jun 01
Terminated
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients Start of enrollment: 2009 Sep 01
Terminated
Phase 3
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment Start of enrollment: 2019 Nov 22
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

407 citations
Nuclear Overexpression of p53 Protein in Transitional Cell Bladder Carcinoma: A Marker for Disease Progression
Alvaro S. Sarkis, Guido Dalbagni, Carlos Cordon-Cardo, Zuo-Feng Zhang, Joel Sheinfeld
Journal of the National Cancer Institute. 1993-01-06
173 citations
Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Mult...
Paolo Gontero, Richard Sylvester, Francesca Pisano, Steven Joniau, Kathy Vander Eeckt
European Urology. 2015-01-01
29 citations
Clinical Outcome of Primary Versus Secondary Bladder Carcinoma In Situ
Daher C. Chade, Shahrokh F. Shariat, Ari Adamy, Bernard H. Bochner, S. Machele Donat
The Journal of Urology. 2010-08-01

Professional Memberships

American College of Surgeons - ACS
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Aetna Whole Health Banner Health Network
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
HealthAmerica HealthAssurance PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment